|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | MDS Analytical Technologies (NYSE:MDZ), a maker of mass spectrometry systems and molecular devices for high-performance bioanalytical measurement. |
|---|---|
| Transferring Party | Blueshift Biotechnologies Inc., a developer of high throughput screening platforms for life sciences research. |
| Sector | Diagnostics |
| Date | June 27, 2008 |
| Analysis Expands MDS' capabilities in cellular analysis and strengthens its global sales and service offering. There are only 14 IsoCyte instruments installed in North America, and MDS feels with its extensive global sales force, it has the ability to bring this product to a wider global market. Deal value -- $13m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |